Oncolytics Biotech Inc. (TSE:ONC – Get Free Report) shares crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of C$1.40 and traded as high as C$1.40. Oncolytics Biotech shares last traded at C$1.40, with a volume of 181,909 shares trading hands.
Analyst Ratings Changes
Separately, Raymond James raised shares of Oncolytics Biotech to a “moderate buy” rating in a research note on Thursday, November 14th.
View Our Latest Stock Analysis on ONC
Oncolytics Biotech Stock Up 6.1 %
About Oncolytics Biotech
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
See Also
- Five stocks we like better than Oncolytics Biotech
- Manufacturing Stocks Investing
- Insiders Are Selling, But These 3 Stocks Are Must-Buys
- How Can Investors Benefit From After-Hours Trading
- Rivian Defies Doubters: Delivery Triumph Fuels Stock Surge
- Basic Materials Stocks Investing
- Hindenburg Short Report Slams Carvana Over Alleged ‘Grift’
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.